TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers
Brief Summary: RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit smoking.

PURPOSE: This randomized clinical trial is studying varenicline to see how well it works compared with the nicotine patch given together with nicotine gum in helping smokers in a methadone treatment program stop smoking.


Options:
A: Arm Label: Treatment as Usual Group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment as Usual Group 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group 1; Type: EXPERIMENTAL; Interventions: Behavioral: Computer Screening, Brief Intervention, Referral toTreatment | Arm Label: Intervention Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Computer Screening, Brief Intervention, Referral toTreatment | Intervention Type: BEHAVIORAL; Name: Computer Screening, Brief Intervention, Referral toTreatment; Assigned to Arm(s): Intervention Group 1, Intervention Group 2
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Extended IVR (integrated voice response technology), Drug: Varenicline (Champix), Behavioral: IVR treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline (Champix), Behavioral: IVR treatment | Intervention Type: BEHAVIORAL; Name: Extended IVR (integrated voice response technology); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline (Champix); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: IVR treatment; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers
Brief Summary: RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit smoking.

PURPOSE: This randomized clinical trial is studying varenicline to see how well it works compared with the nicotine patch given together with nicotine gum in helping smokers in a methadone treatment program stop smoking.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: Extended Brief Contact; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Check-ins with medical staff | Arm Label: Extended Health Education; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Health Model | Arm Label: Extended Relapse Prevention plus varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Relapse Prevention Model | Arm Label: Extended Relapse Prevention; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Initial Individual counseling, Behavioral: Extended Individual Counseling - Relapse Prevention Model | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Extended Brief Contact, Extended Health Education, Extended Relapse Prevention, Extended Relapse Prevention plus varenicline | Intervention Type: BEHAVIORAL; Name: Initial Individual counseling; Assigned to Arm(s): Extended Brief Contact, Extended Health Education, Extended Relapse Prevention, Extended Relapse Prevention plus varenicline | Intervention Type: BEHAVIORAL; Name: Check-ins with medical staff; Assigned to Arm(s): Extended Brief Contact | Intervention Type: BEHAVIORAL; Name: Extended Individual Counseling - Health Model; Assigned to Arm(s): Extended Health Education | Intervention Type: BEHAVIORAL; Name: Extended Individual Counseling - Relapse Prevention Model; Assigned to Arm(s): Extended Relapse Prevention, Extended Relapse Prevention plus varenicline
C: Intervention Type: DRUG; Name: SSR591813L (dianicline); Assigned to Arm(s): N/A
D: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease
Brief Summary: The purpose of this multicenter, open-label study is to collect data on the occurrence of important clinical safety events resulting from chronic vedolizumab (MLN0002) administration.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Vedolizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Vedolizumab | Intervention Type: DRUG; Name: Vedolizumab; Assigned to Arm(s): Vedolizumab 300 mg
D: Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The SASA! Study: a Cluster Randomised Controlled Trial of a Community Mobilisation Intervention to Prevention Violence Against Women and Reduce HIV/AIDS Risk in Kampala, Uganda
Brief Summary: The SASA! Study is a cluster randomized trial of a community mobilization intervention for the prevention of HIV and gender based violence. The study is being conducted in Kampala, Uganda.


Options:
A: Arm Label: SASA!; Type: EXPERIMENTAL; Interventions: Behavioral: SASA! | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: SASA!; Assigned to Arm(s): SASA! | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Clinics trained in brief intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Family Planning-based Partner Violence Intervention | Arm Label: Control sites providing standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Family Planning-based Partner Violence Intervention; Assigned to Arm(s): Clinics trained in brief intervention
C: Arm Label: Brief Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement Therapy | Arm Label: Assessed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Contact Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Therapy; Assigned to Arm(s): Brief Intervention Group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Public Health Nurse Home Visit | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intimate Partner Violence (IPV) Protocol | Intervention Type: BEHAVIORAL; Name: Public Health Nurse Home Visit; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Intimate Partner Violence (IPV) Protocol; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The SASA! Study: a Cluster Randomised Controlled Trial of a Community Mobilisation Intervention to Prevention Violence Against Women and Reduce HIV/AIDS Risk in Kampala, Uganda
Brief Summary: The SASA! Study is a cluster randomized trial of a community mobilization intervention for the prevention of HIV and gender based violence. The study is being conducted in Kampala, Uganda.


Options:
A: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: The SHARE Project | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The SHARE Project; Assigned to Arm(s): Intervention arm
B: Arm Label: SASA!; Type: EXPERIMENTAL; Interventions: Behavioral: SASA! | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: SASA!; Assigned to Arm(s): SASA! | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: RHANI Wives Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: RHANI WIves | Intervention Type: BEHAVIORAL; Name: RHANI WIves; Assigned to Arm(s): RHANI Wives Intervention
D: Arm Label: Internet Based Safety Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based safety decision aid | Arm Label: Control Website; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Safety Plan | Intervention Type: BEHAVIORAL; Name: Internet-based safety decision aid; Assigned to Arm(s): Internet Based Safety Decision Aid | Intervention Type: BEHAVIORAL; Name: Usual Care Safety Plan; Assigned to Arm(s): Control Website

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery
Brief Summary: Aim1a: Statin naive patient's scheduled for cardiac surgery will be randomized to 80mg atorvastatin or placebo on the day prior to surgery and then 40mg daily thereafter until hospital discharge to test the hypothesis that short-term atorvastatin use decreases:

1. acute kidney injury following cardiac surgery.
2. postoperative delirium following cardiac surgery.

Aim1b: Patients using statins preoperatively will be randomized to atorvastatin 80mg or placebo on day of surgery and 40mg or placebo on postop day 1 with resumption of preoperative statin therapy on postop day 2 to test the hypothesis that short-term atorvastatin use decreases:

1. acute kidney injury following cardiac surgery.
2. postoperative delirium following cardiac surgery.

Endpoints include glomerular filtration, urine and plasma markers of renal dysfunction, markers of oxidative stress, mitochondrial function, systemic inflammatory markers, delirium, dialysis, stroke, myocardial infarction, time to extubation, ICU length of stay, and death.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: atorvastatin | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): 1
B: Arm Label: Atorvastatin, Ischemic Heart Disease; Type: OTHER; Interventions: Drug: Atorvastatin, high vs low dose | Arm Label: Atorvastatin vs Placebo Cardiac Surgery; Type: PLACEBO_COMPARATOR; Interventions: Drug: Atorvastatin vs Placebo | Intervention Type: DRUG; Name: Atorvastatin, high vs low dose; Assigned to Arm(s): Atorvastatin, Ischemic Heart Disease | Intervention Type: DRUG; Name: Atorvastatin vs Placebo; Assigned to Arm(s): Atorvastatin vs Placebo Cardiac Surgery
C: Arm Label: statin; Type: EXPERIMENTAL; Interventions: Drug: atorvastatin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): statin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rosuvastatin | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: rosuvastatin | Intervention Type: DRUG; Name: rosuvastatin; Assigned to Arm(s): 1, control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery
Brief Summary: Aim1a: Statin naive patient's scheduled for cardiac surgery will be randomized to 80mg atorvastatin or placebo on the day prior to surgery and then 40mg daily thereafter until hospital discharge to test the hypothesis that short-term atorvastatin use decreases:

1. acute kidney injury following cardiac surgery.
2. postoperative delirium following cardiac surgery.

Aim1b: Patients using statins preoperatively will be randomized to atorvastatin 80mg or placebo on day of surgery and 40mg or placebo on postop day 1 with resumption of preoperative statin therapy on postop day 2 to test the hypothesis that short-term atorvastatin use decreases:

1. acute kidney injury following cardiac surgery.
2. postoperative delirium following cardiac surgery.

Endpoints include glomerular filtration, urine and plasma markers of renal dysfunction, markers of oxidative stress, mitochondrial function, systemic inflammatory markers, delirium, dialysis, stroke, myocardial infarction, time to extubation, ICU length of stay, and death.


Options:
A: Arm Label: statin; Type: EXPERIMENTAL; Interventions: Drug: atorvastatin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): statin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: Rosuvastatin calcium; Assigned to Arm(s): N/A
C: Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar pill
D: Intervention Type: DRUG; Name: CRESTOR; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label Trial Concerning the Effectiveness of Trazodone in the Treatment of Fibromyalgia (Phase I) and Its Augmentation With Pregabalin in Trazodone Partial Responders (Phase II)
Brief Summary: The study has a double purpose: a first phase intends to assess the effectiveness and tolerability of trazodone, an antidepressant with sedative and sleep-promoting properties, in the treatment of fibromyalgia; a second phase intends to evaluate if the addition of pregabalin to patients who have shown a partial response to trazodone additionally improves fibromyalgia symptomatology.


Options:
A: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Arm Label: one arm study; Type: EXPERIMENTAL; Interventions: Drug: trazodone, pregabalin | Intervention Type: DRUG; Name: trazodone, pregabalin; Assigned to Arm(s): one arm study
C: Intervention Type: DRUG; Name: Intravenous micronutrient therapy; Assigned to Arm(s): N/A
D: Arm Label: Melatonin and Placebo; Type: EXPERIMENTAL; Interventions: Drug: Melatonin and Placebo | Arm Label: Amitriptyline and placebo; Type: EXPERIMENTAL; Interventions: Drug: Amitriptyline and Placebo | Arm Label: Melatonin and Amitriptylin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melatonin and Amitriptylin | Intervention Type: DRUG; Name: Melatonin and Placebo; Assigned to Arm(s): Melatonin and Placebo | Intervention Type: DRUG; Name: Amitriptyline and Placebo; Assigned to Arm(s): Amitriptyline and placebo | Intervention Type: DRUG; Name: Melatonin and Amitriptylin; Assigned to Arm(s): Melatonin and Amitriptylin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy
Brief Summary: Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen of chemotherapy.


Options:
A: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: topotecan; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab
B: Arm Label: BIBF 1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): BIBF 1120 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): BIBF 1120
C: Arm Label: Tivozanib; Type: EXPERIMENTAL; Interventions: Drug: Tivozanib | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Tivozanib; Assigned to Arm(s): Tivozanib
D: Arm Label: Sorafenib (Nexavar, BAY43-9006); Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): Sorafenib (Nexavar, BAY43-9006) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy
Brief Summary: Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen of chemotherapy.


Options:
A: Arm Label: chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: pegylated liposomal doxorubicin, Drug: Gemcitabine | Arm Label: Chemotherapy and bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin, Drug: pegylated liposomal doxorubicin, Drug: Gemcitabine | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy and bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy
B: Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): N/A
C: Arm Label: BI 6727; Type: EXPERIMENTAL; Interventions: Drug: BI 6727 | Arm Label: Cytotoxic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Gemcitabine, Drug: Topotecan, Drug: Pegylated liposomal doxorubicin (PLD) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: BI 6727; Assigned to Arm(s): BI 6727
D: Arm Label: Sorafenib (Nexavar, BAY43-9006); Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): Sorafenib (Nexavar, BAY43-9006) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D